{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:23:23Z","timestamp":1715977403134},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2012,11,2]],"date-time":"2012-11-02T00:00:00Z","timestamp":1351814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["clinical-practice-and-epidemiology-in-mental-health.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["CPEMH"],"published-print":{"date-parts":[[2012,11,2]]},"abstract":"<jats:sec><jats:title>Objective:<\/jats:title><jats:p>Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric\/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The sample included 165 patients, affected by anxiety and\/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Most common primary diagnoses were MDD (49.1 %), Bipolar Disorder (BD) (15.7 %) and GAD (5.5%). The 40 % of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 %) (GAD 7.9%, Panic Disorder \u2013PD- 7.3%) and personality disorders (9.1%) as the most frequent ones. With respect to medical comorbidities (68% of the sample), hypertension (12.1%) and diabetes (7.3%) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (\u00b1 9.1) and 70 mg\/day (\u00b1 28.6). The 68 % of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 % of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Duloxetine, mostly administered in patients with affective disorders with psychiatric\/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1745017901208010120","type":"journal-article","created":{"date-parts":[[2012,11,12]],"date-time":"2012-11-12T10:44:29Z","timestamp":1352717069000},"page":"120-125","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Duloxetine in Affective Disorders: a Naturalistic Study on Psychiatric and Medical Comorbidity, Use in Association and Tolerability Across Different Age Groups"],"prefix":"10.2174","volume":"8","author":[{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Camuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Dobrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Buoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Serati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carlo Altamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hup.1074","volume":"25","author":"Dell'Osso B","year":"2010","unstructured":"Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy Hum Psychopharmacol 2010; 25 : 17-29.","journal-title":"Hum Psychopharmacol"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/PCC.v05n0105","volume":"5","author":"Sussman N","year":"2003","unstructured":"Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms Prim Care Companion J Clin Psychiatry 2003; 5 : 19-26.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"refR3","first-page":"23","volume":"5","author":"Khan AY","year":"2009","unstructured":"Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review Neuropsychiatr Dis Treat 2009; 5 : 23-31.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00023210-200923060-00006","volume":"23","author":"Carter NJ","year":"2009","unstructured":"Carter NJ, McCormack PL. Duloxetine. A review of its use in the treatment of generalized anxiety disorder CNS Drugs 2009; 23 : 523-0.","journal-title":"CNS Drugs"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.31.9.1142","volume":"31","author":"Lantz RJ","year":"2003","unstructured":"Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects Drug Metab Dispos 2003; 31 : 1142-50.","journal-title":"Drug Metab Dispos"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.bmcl.2004.04.066","volume":"14","author":"Kuo F","year":"2004","unstructured":"Kuo F, Gillespie TA, Kulanthaivel P, et al. Synthesis and biological activation of some known and putative duloxetine metabolites Bioorg Med Chem Lett 2004; 14 : 3481-6.","journal-title":"Bioorg Med Chem Lett"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"Spina E","year":"2008","unstructured":"Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants an update Clin Ther 2008; 30 : 1206-27.","journal-title":"Clin Ther"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","volume":"25","author":"Bymaster FP","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors Neuropsychopharmacol 2001; 25 : 871-0.","journal-title":"Neuropsychopharmacol"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hup.696","volume":"20","author":"Hudson JI","year":"2005","unstructured":"Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials Hum Psychopharmacol 2005; 20 : 327-41.","journal-title":"Hum Psychopharmacol"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4306\/pi.2010.7.3.228","volume":"7","author":"Park YM","year":"2010","unstructured":"Park YM, Lee BH, Lee HJ, Kang SG. Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder Psychiatry Investig 2010; 7 : 228-30.","journal-title":"Psychiatry Investig"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jad.2011.07.026","volume":"136","author":"Rosso G","year":"2012","unstructured":"Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, singleblind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression J Affect Disord 2012; 136 : 172-6.","journal-title":"J Affect Disord"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hup.1199","volume":"26","author":"Sheehan DV","year":"2011","unstructured":"Sheehan DV, Chokka PR, Granger RE, Walton RJ, Raskin J, Sagman D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine Hum Psychopharmacol 2011; 26 : 242-51.","journal-title":"Hum Psychopharmacol"},{"key":"refR13","first-page":"S106","volume":"22","author":"Pitchot W","year":"2010","unstructured":"Pitchot W, Scantamburlo G, Ansseau M. Duloxetine in major depressed patients resistant to SSRIs and\/or venlafaxine Psychiatr Danub 2010; 22 : S106-7.","journal-title":"Psychiatr Danub"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1742-1241.2010.02374.x","volume":"64","author":"Kelin K","year":"2010","unstructured":"Kelin K, Berk M, Spann M J, et al. Duloxetine 60 mg\/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study Int J Clin Pract 2010; 64 : 719-26.","journal-title":"Int J Clin Pract"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","volume":"342","author":"Baldwin D","year":"2011","unstructured":"Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis BMJ 2011; 342 : d1199-0.","journal-title":"BMJ"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.janxdis.2009.07.008","volume":"23","author":"Beesdo K","year":"2009","unstructured":"Beesdo K, Hartford J, Russell J, Spann M, Ball S, Wittchen HU. The short term and long term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: Result from three clinical trials J Anxiety Disord 2009; 23 : 1064-71.","journal-title":"J Anxiety Disord"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/03007995.2011.576663","volume":"27","author":"Wang J","year":"2011","unstructured":"Wang J, Liu X, Mullins CD. Treatment adherence and persistence with Duloxetine, Venlafaxine XR, and Escitalopram among patients with major depressive disorder and chronic pain-related diseases Curr Med Res Opin 2011; 27 : 1303-.","journal-title":"Curr Med Res Opin"},{"key":"refR18","first-page":"321","volume":"161","author":"Serafini G","year":"2010","unstructured":"Serafini G, Pompili M, Del Casale A, et al. Duloxetine versus venlafaxine in the treatment of unipolar and bipolar depression Clin Ther 2010; 161 : 321-7.","journal-title":"Clin Ther"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1742-1241.2007.01476.x","volume":"61","author":"Wise E","year":"2007","unstructured":"Wise E, Wiltse CG, Iosifescu DV, Sheridan M, Xu YY, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity Int J Clin Pract 2007; 61 : 1283-93.","journal-title":"Int J Clin Pract"},{"key":"refR20","unstructured":"American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press 2000."},{"key":"refR21","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I\/NP). New York: Biometrics Research, New York State Psychiatric Institute 2002."},{"key":"refR22","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, D.C: American Psychiatric Press, Inc 1997."},{"key":"refR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"Hamilton M","year":"1960","unstructured":"Hamilton M. A Rating Scale for Depression, Department of Psychiatry, University of Leeds J Neurol Neurosurg Psychiatry 1960; 23 : 56-62.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"Hamilton M","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating Br J Med Psychol 1959; 32 : 50-.","journal-title":"Br J Med Psychol"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"Montgomery SA","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change Br J Psychiatry 1979; 134 : 382-9.","journal-title":"Br J Psychiatry"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"Young RC","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity Br J Psychiatry 1978; 133 : 429-35.","journal-title":"Br J Psychiatry"},{"key":"refR27","doi-asserted-by":"crossref","unstructured":"Guy W. Clinical Global Impressions: In ECDEU Assessment Manual for Psychopharmacology Revised DHEW Pub. Rockville, MD: National Institute for Mental Health 1976; pp. 218-2.","DOI":"10.1037\/e591322011-001"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jad.2009.06.043","volume":"117","author":"Sidney HK","year":"2009","unstructured":"Sidney HK, Raymond WL, Sagar VP, Scott BP, Arun VR. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults J Affect Disord 2009; 117 : S1-2.","journal-title":"J Affect Disord"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"Bandelow B","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, et al. WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive disorder and post-traumatic stress disorder W J Biol Psychiatry 2008; 9 : 248-312.","journal-title":"W J Biol Psychiatry"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0269881108089841","volume":"23","author":"Peritogiannis V","year":"2009","unstructured":"Peritogiannis V, Antoniou K, Mouka V, Mavreas V, Hyphantis TN. Duloxetine-induced hypomania: case report and brief review of the literature on SNRIs-induced mood switching J Psychopharmacol 2009; 23 : 592-6.","journal-title":"J Psychopharmacol"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2146\/ajhp050006","volume":"62","author":"Westanmo AD","year":"2005","unstructured":"Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor Am J Health Syst Pharm 2005; 62 : 2481-90.","journal-title":"Am J Health Syst Pharm"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1345\/aph.1E084","volume":"38","author":"Dugan SE","year":"2004","unstructured":"Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor Ann Pharmacother 2004; 38 : 2078-85.","journal-title":"Ann Pharmacother"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1185\/03007991003769241","volume":"26","author":"Crucitti A","year":"2010","unstructured":"Crucitti A, Zhang Q, Nilsson M, Brecht S, Yang CR, Wernicke J. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a metaanalysis Curr Med Res Opin 2010; 26 : 2579-88.","journal-title":"Curr Med Res Opin"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4088\/PCC.v08n0503","volume":"8","author":"Wise TN","year":"2006","unstructured":"Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies Prim Care Companion J Clin Psychiatry 2006; 8 : 269-78.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1742-1241.2007.01476.x","volume":"61","author":"Wise TN","year":"2007","unstructured":"Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity Int J Clin Pract 2007; 61 : 1283-93.","journal-title":"Int J Clin Pract"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/14737175.9.2.155","volume":"9","author":"Kornstein SG","year":"2009","unstructured":"Kornstein SG, Russell JM, Spann ME, Crits-Christoph P, Ball SG. Duloxetine in the treatment of generalized anxiety disorder Expert Rev Neurother 2009; 9 : 155-65.","journal-title":"Expert Rev Neurother"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/00023210-200721070-00004","volume":"21","author":"Frampton JE","year":"2007","unstructured":"Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder CNS Drugs 2007; 21 : 581-609.","journal-title":"CNS Drugs"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4088\/JCP.09m05723blu","volume":"72","author":"Brecht S","year":"2010","unstructured":"Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial J Clin Psychiatry 2010; 72 : 1086-94.","journal-title":"J Clin Psychiatry"},{"key":"refR39","first-page":"258","volume":"13","author":"Tarolla E","year":"2007","unstructured":"Tarolla E, Brugnoli R, Pacheri P. Duloxetine: clinical efficacy, safety and tolerability in treatment of major depression Giron ital PsicoPat 2007; 13 : 258-78.","journal-title":"Giron ital PsicoPat"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11537140-000000000-00000","volume":"28","author":"Dolder C","year":"2010","unstructured":"Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients Drugs Aging 2010; 28 : 625-40.","journal-title":"Drugs Aging"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","volume":"47","author":"Lobo ED","year":"2008","unstructured":"Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine Clin Pharmacokinet 2008; 47 : 191-202.","journal-title":"Clin Pharmacokinet"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","volume":"50","author":"Knadler MP","year":"2011","unstructured":"Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions Clin Pharmacokinet 2011; 50 : 281-94.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Practice &amp; Epidemiology in Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V8\/CPEMH-8-120\/CPEMH-8-120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V8\/CPEMH-8-120\/CPEMH-8-120.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V8\/CPEMH-8-120\/CPEMH-8-120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T08:34:22Z","timestamp":1714552462000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/VOLUME\/8\/PAGE\/120\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,11,2]]}},"alternative-id":["CPEMH-8-120"],"URL":"https:\/\/doi.org\/10.2174\/1745017901208010120","relation":{},"ISSN":["1745-0179"],"issn-type":[{"value":"1745-0179","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2012-1-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-5-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-6-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-2","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}